New Published Data Show Pluristem's PLX Cells Protect Neurons
GlobeNewswire - Mon Dec 22, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
When Considering Cell Therapy Investments - Not All Cells Are the Same
ACCESSWIRE - Thu Dec 18, 9:14AM CST
LOS ANGELES, CA / ACCESSWIRE / December 18, 2014 / BioMedReports.com's editor, Dusty Garza, spoke with Pluristem Therapeutics' (NASDAQ
PSTI: 2.46 (unch)
Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)
Intermittent Claudication - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmx9/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2013" report to their offering. 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Nissan Chemical Industries, Ltd. - Sangamo BioSciences, Inc. - Rigel Pharmaceuticals, Inc. - Sigma-Tau S.p.A. - Cytokinetics, Incorporated - Cytomedix, Inc. - Pluristem Therapeutics Inc. - LTT Bio-Pharma Co., Ltd. - Taisho Toyama Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/59...termittent
CYTK: 5.87 (+0.35), PSTI: 2.46 (unch), SGMO: 14.20 (+0.14), RIGL: 2.22 (+0.02)
Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:01AM CST
Pluristem Therapeutics has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
PSTI: 2.46 (unch)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.46 (unch)
Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
GlobeNewswire - Thu Dec 04, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 140.33 (-0.22), PSTI: 2.46 (unch), EXEL: 1.29 (-0.01)
Pluristem wins patent for 3D cell expansion technology in Singapore
M2 - Mon Dec 01, 7:22AM CST
Cell therapy products company Pluristem Therapeutics (NasdaqCM
PSTI: 2.46 (unch)
Pluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology
GlobeNewswire - Mon Dec 01, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
Pluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences
GlobeNewswire - Tue Nov 25, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
Pluristem posts 1Q loss
Automated Insights - Fri Nov 21, 6:15AM CST
HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Friday reported a loss of $5.9 million, or 9 cents per share, in its fiscal first quarter.
PSTI: 2.46 (unch)
Pluristem wins patents in Australia and New Zealand for placental cells for treating orthopedic, nerve injury and neurodegenerative diseases
M2 - Wed Nov 12, 6:25AM CST
Placenta cell therapy company Pluristem Therapeutics (NasdaqCM
PSTI: 2.46 (unch)
Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications
GlobeNewswire - Wed Nov 12, 2:35AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014
GlobeNewswire - Mon Nov 10, 2:00AM CST
London Regenerative Medicine Network Meeting
PSTI: 2.46 (unch)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), PSTI: 2.46 (unch), NBS: 3.27 (+0.02), ALDR: 25.67 (+0.43), IDRA: 3.89 (+0.02), SGEN: 31.10 (-0.14), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), KMDA: 3.57 (-0.03), ATHX: 1.30 (-0.03), NVS: 93.91 (+0.66)
Pluristem Therapeutics Developing Off-The-Shelf Cell Therapy to Cure Blood Cancers and Treat Radiation Sickness
ACCESSWIRE - Wed Nov 05, 7:40AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Innovation is the root of Pluristem Therapeutics's (PSTI:NASDAQ) technology, and its latest offering, PLX-RAD cells represent a new line of allogenic off-the-shelf therapy with two distinct and vital applications - bone marrow transplant (BMT) and acute radiation syndrome (ARS). PLX-RAD cells are specifically engineered to treat blood cancers and restore healthy bone marrow function following chemotherapy, radiation therapy, and radiation exposure resulting from a nuclear or terrorist dirty bomb.
PSTI: 2.46 (unch)
The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:21AM CDT
The Spectranetics Corporation (SPNC) was a big mover last session, as the company saw its shares soar by over 13% on the day.
SPNC: 34.50 (+0.59), VRX: 140.33 (-0.22), PSTI: 2.46 (unch), MYL: 56.97 (+0.39)
Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases
GlobeNewswire - Mon Oct 27, 2:59AM CDT
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.46 (unch)
Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.46 (unch), UTHR: 130.22 (+2.40), OSIR: 14.87 (+0.13), ATHX: 1.30 (-0.03)